193 related articles for article (PubMed ID: 16362261)
1. [Cutaneous lesions due to inhibition of epidermal growth factor receptor].
Bierhoff E; Seifert HW; Dirschka T
Pathologe; 2006 Feb; 27(1):53-6. PubMed ID: 16362261
[TBL] [Abstract][Full Text] [Related]
2. [Management of cutaneous toxicities induced by epidermal growth factor receptor inhibitors: a review].
Mestdagh K; Fink W; Hendlisz A; Heenen M; Vereecken P
Rev Med Brux; 2008; 29(6):552-8. PubMed ID: 19202711
[TBL] [Abstract][Full Text] [Related]
3. [Cutaneous side effects of EGF-receptor inhibition and their management].
Gutzmer R; Werfel T; Kapp A; Elsner J
Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
[TBL] [Abstract][Full Text] [Related]
4. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
6. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
Lacouture ME; Melosky BL
Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
[TBL] [Abstract][Full Text] [Related]
8. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
Lien K; Berry S; Ko YJ; Chan KK
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
10. [Cutaneous side effects of EGF receptor inhibitors].
Nassar D; Soutou B; Aractingi S
Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
[TBL] [Abstract][Full Text] [Related]
11. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
12. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
13. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review.
Baas JM; Krens LL; Guchelaar HJ; Ouwerkerk J; de Jong FA; Lavrijsen AP; Gelderblom H
Cancer Treat Rev; 2012 Aug; 38(5):505-14. PubMed ID: 22100458
[TBL] [Abstract][Full Text] [Related]
14. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab.
Garibaldi DC; Adler RA
Ophthalmic Plast Reconstr Surg; 2007; 23(1):62-3. PubMed ID: 17237696
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.
Vanhoefer U; Tewes M; Rojo F; Dirsch O; Schleucher N; Rosen O; Tillner J; Kovar A; Braun AH; Trarbach T; Seeber S; Harstrick A; Baselga J
J Clin Oncol; 2004 Jan; 22(1):175-84. PubMed ID: 14701780
[TBL] [Abstract][Full Text] [Related]
16. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis.
Tomková H; Pospíšková M; Zábojníková M; Kohoutek M; Serclová M; Gharibyar M; Sternberský J
J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):514-9. PubMed ID: 22035385
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
[TBL] [Abstract][Full Text] [Related]
18. [Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
Tjin-A-ton ML; van Montfrans C; Koldenhof JJ; Sigurdsson V; Voest EE; Witteveen PO
Ned Tijdschr Geneeskd; 2007 Apr; 151(17):945-52. PubMed ID: 17520845
[TBL] [Abstract][Full Text] [Related]
19. [Acneiform skin eruption in patients with metastatic colorectal carcinoma].
Gethöffer K; Schneider LA; Peters T; Weber L; Scharffetter-Kochanek K
Hautarzt; 2006 Jul; 57(7):628-31. PubMed ID: 16034631
[No Abstract] [Full Text] [Related]
20. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.
Santiago F; Gonçalo M; Reis JP; Figueiredo A
An Bras Dermatol; 2011; 86(3):483-90. PubMed ID: 21738965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]